---
schema_version: "secwatch.filing_event.v1"
accession: "0000899923-23-000052"
form_type: "8-K"
ticker: "MYGN"
cik: "0000899923"
company_name: "MYRIAD GENETICS INC"
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T10:39:19.276822+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Myriad Genetics Q2 revenue $183.5M, settles securities class action for $77.5M

## Summary
- Q2 revenue $183.5M, up 2% YoY; diluted GAAP EPS $(1.42), adjusted EPS $(0.08).
- Test volume grew 38% YoY (17% ex-SneakPeek); hereditary cancer volume up 20% YoY.
- Agreed to settle securities class action for $77.5M: $20M cash in Q3 2023, remainder in cash or stock by Q1 2024.
- Reaffirmed FY2023 revenue guidance $730-750M; adjusted EPS loss $(0.36)-(0.24); targeting positive adjusted profitability in Q4.
- Established new $90M asset-based credit facility (option to $115M); ended Q2 with $127.8M cash.

## SEC filing metadata
- accession: 0000899923-23-000052
- form_type: 8-K
- ticker: MYGN
- cik: 0000899923
- company_name: MYRIAD GENETICS INC
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899923/000089992323000052/0000899923-23-000052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899923/000089992323000052/mygn-20230803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000899923-23-000052
- JSON: https://secwatch.observer/filing/0000899923-23-000052.json
- Plain text: https://secwatch.observer/filing/0000899923-23-000052.txt

## Key facts
- Earnings Releases
  MYRIAD GENETICS INC reported second quarter ended June 30, 2023 results: revenue $183.5 million, EPS $(1.42). Guidance reaffirmed.
  - Period: second quarter ended June 30, 2023
  - Revenue: $183.5 million
  - EPS: $(1.42)
  - Guidance: reaffirmed
  - Result: reported results
  source text: volumes grew 23% year-over-year. ▪ Prenatal test volumes grew 12% year-over-year, excluding contributions from the SneakPeek Early Gender DNA Test. • Second quarter revenue of $183.5 million, grew 2% year-over-year, inclusive of a $11.7 million change of estimate in the second quarter of 2022 versus an immaterial amount in the current quarter. Excluding these change
  evidence_url: https://www.sec.gov/Archives/edgar/data/899923/000089992323000052/0000899923-23-000052-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.